MultiHance in the dynamic phase of contrast enhancement: a pictorial assessment.
The present article demonstrates pictorially the use of MultiHance (gadobenate dimeglumine, Gd-BOPTA) in dynamic magnetic resonance imaging and is aimed at ensuring that the product is not misconceived as solely a hepatobiliary agent for use in delayed, static magnetic resonance imaging for the improved detection of focal liver lesions. The enhancement patterns of three malignant (hepatocellular carcinoma, cholangiocarcinoma and metastasis) and three benign (hemangioma, focal nodular hyperplasia and adenoma) lesion types are demonstrated. Each was imaged during the dynamic phase of contrast enhancement immediately following the intravenous bolus administration of 0.05 mmol/kg MultiHance. The article demonstrates that the enhancement patterns observed for these relatively common lesions are similar to those reported in the literature after the intravenous bolus administration of conventional, non-specific 'extracellular fluid' contrast agents, and concludes by inferring that MultiHance behaves in the liver as a conventional gadolinium-based agent in the first minutes after administration.